Dopamine receptor D2 on CD4+ T cells is protective against neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease
Sign Up to like & getrecommendations! Published in 2021 at "Brain, Behavior, and Immunity"
DOI: 10.1016/j.bbi.2021.08.220
Abstract: Parkinson's disease (PD) is a chronic neurodegenerative disease. Recently, neuroinflammation driven by CD4+ T cells has been involved in PD pathophysiology. Human and murine lymphocytes express all the five subtypes of dopamine receptors (DRs), DRD1… read more here.
Keywords: cd4 cells; disease; neurodegeneration; drd2 ... See more keywords
Investigating the role of striatal dopamine receptor 2 in motor coordination and balance: Insights into the pathogenesis of DYT1 dystonia
Sign Up to like & getrecommendations! Published in 2021 at "Behavioural Brain Research"
DOI: 10.1016/j.bbr.2021.113137
Abstract: DYT1 or DYT-TOR1A dystonia is early-onset, generalized dystonia. Most DYT1 dystonia patients have a heterozygous trinucleotide GAG deletion in DYT1 or TOR1A gene, with a loss of a glutamic acid residue of the protein torsinA.… read more here.
Keywords: dyt1; dyt1 dystonia; motor; drd2 ... See more keywords
Variation on the dopamine D2 receptor gene (DRD2) is associated with basal ganglia-to-frontal structural connectivity
Sign Up to like & getrecommendations! Published in 2017 at "NeuroImage"
DOI: 10.1016/j.neuroimage.2017.04.005
Abstract: ABSTRACT Dopaminergic neurotransmission in the mesocortical system is crucial for higher order cognition. Common variation on the dopamine D2 receptor (DRD2) gene has been linked to individual differences in dopaminergic signaling and was also repeatedly… read more here.
Keywords: ganglia frontal; connectivity; dopamine; integrity ... See more keywords
Developing Photoaffinity Probes for Dopamine Receptor D2 to Determine Targets of Parkinson’s Disease Drugs
Sign Up to like & getrecommendations! Published in 2022 at "ACS Chemical Neuroscience"
DOI: 10.1021/acschemneuro.2c00544
Abstract: Dopaminergic pathways control highly consequential aspects of physiology and behavior. One of the most therapeutically important and best-studied receptors in these pathways is dopamine receptor D2 (DRD2). Unfortunately, DRD2 is challenging to study with traditional… read more here.
Keywords: drd2; dopamine receptor; photoaffinity; parkinson disease ... See more keywords
STRUCTURE OF THE D2 DOPAMINE RECEPTOR BOUND TO THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE
Sign Up to like & getrecommendations! Published in 2018 at "Nature"
DOI: 10.1038/nature25758
Abstract: Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metabolism and hormonal secretion. Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such… read more here.
Keywords: atypical antipsychotic; antipsychotic drug; structure; drd2 ... See more keywords
Olfactory regulation by dopamine and DRD2 receptor in the nose
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2118570119
Abstract: Significance Despite the identification of neural circuits and circulating hormones in olfactory regulation, the peripheral targets for olfactory modulation remain relatively unexplored. Here we show that dopamine D2 receptor (DRD2) is expressed in the cilia… read more here.
Keywords: olfactory regulation; dopamine; drd2; drd2 receptor ... See more keywords
EXTH-74. IND-ENABLING CHARACTERIZATION OF DUAL DRD2- AND ClpP-TARGETING AGENT ONC206 AS THE NEXT IMIPRIDONE FOR CLINICAL NEURO-ONCOLOGY
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-oncology"
DOI: 10.1093/neuonc/noaa215.428
Abstract: ONC201 is the first bitopic antagonist of dopamine receptor D2 (DRD2) and allosteric mitochondrial protease ClpP agonist, that is well tolerated and induces durable tumor regressions in H3 K27M-mutant glioma patients. ONC206, a derivative of… read more here.
Keywords: onc206; cell lines; clpp; neuro oncology ... See more keywords
REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-oncology"
DOI: 10.1093/neuonc/noz030
Abstract: BACKGROUND Glioblastoma (GBM) is a lethal, heterogeneous human brain tumor, with regulatory mechanisms that have yet to be fully characterized. Previous studies have indicated that the transcriptional repressor REST (repressor element-1 silencing transcription factor) regulates… read more here.
Keywords: rest drd2; tumorigenesis; gbm; drd2 mechanism ... See more keywords
Abstract A060: Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses
Sign Up to like & getrecommendations! Published in 2018 at "Biomarkers"
DOI: 10.1158/1535-7163.targ-17-a060
Abstract: Background: ONC201, an imipridone that is a selective antagonist of the G protein-coupled receptors dopamine receptor D2 (DRD2) and D3 (DRD3), has exhibited biologic activity and an exceptional safety profile in a phase II study… read more here.
Keywords: imipridone; glioblastoma; cancer; drd2 ... See more keywords
Abstract 4874: Receptor pharmacology and anti-cancer activity of selective DRD2/3 antagonist imipridone ONC206
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4874
Abstract: Dopamine receptor D2 (DRD2) is a G protein-coupled receptor (GPCR) overexpressed in many cancers and its antagonism causes anti-tumor effects. ONC201, founding member of the imipridone class of small molecules, is a DRD2 antagonist in… read more here.
Keywords: pharmacology; drd2; drd2 antagonist; cancer ... See more keywords
Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.2586
Abstract: 2586Background: ONC201 is an orally active, small molecule selective antagonist of the G protein-coupled receptor DRD2 that has established a new class of compounds referred to as imipridones. A first-in-human trial of ONC201 defined its… read more here.
Keywords: onc201; anticancer immunostimulatory; immunostimulatory activity; drd2 ... See more keywords